Neurol. praxi. 2016;17(1):60-62 | DOI: 10.36290/neu.2016.012

Remyelination in multiple sclerosis, neuroprotective potential of glatiramer acetate and laquinimode

doc. MUDr. Pavel Štourač, Ph.D.
Neurologická klinika MU a FN Brno

Glatiramer acetate and laquinimode are effective drugs for the treatment of multiple sclerosis.Glatiramer acetate and laquinimode exert significant not only anti-inflammatory effects but also important effects on remyelination and neuroprotection.

Keywords: glatiramer acetate,laquinimode, remyelination, neuroprotection

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P. Remyelination in multiple sclerosis, neuroprotective potential of glatiramer acetate and laquinimode. Neurol. praxi. 2016;17(1):60-62. doi: 10.36290/neu.2016.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    LMm_References

    1. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 2005; 102: 19045-19050. Go to original source... Go to PubMed...
    2. Aharoni R, Herschkovitz A, Eilam R, Blumberg-Hazan M, Sela M, Bruck W, Arnor R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalitis. Proc Natl Acad Sci USA 2008; 105: 11358-11363. Go to original source... Go to PubMed...
    3. Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neurol Transm 2009; 116: 1443-1449. Go to original source... Go to PubMed...
    4. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis.Lancet Neurol 2010; 9: 599-612. Go to original source...
    5. Aschrio A, Munger KL. Enviromental risk factors for multiple sclerosis. Part I - The role of infection. Ann Neurol 2007; 61: 288-299. Go to original source... Go to PubMed...
    6. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011; 306: 173-179. Go to original source... Go to PubMed...
    7. Brunmark C, Runstrom A, Ohlsson L, Spare B, Brodin T, Astrom M, Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. 2002 J Neuroimmunol 130; 163-172. Go to original source... Go to PubMed...
    8. Comi G, Filippi M, Wolinski JS. European /Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297. Go to original source... Go to PubMed...
    9. Comi GC, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Fillippi M. Placebo-Controlled Trial of Oral Laquinimode for Multiple Sclerosis. N Engl J Med 2012; 366: 1000-1009. Go to original source... Go to PubMed...
    10. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M.et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189. Go to original source... Go to PubMed...
    11. Geurts JJ, Barkhof F.Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841-851. Go to original source... Go to PubMed...
    12. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The Genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012;2 48: 87-103. Go to original source... Go to PubMed...
    13. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 2010; 225: 9-17. Go to original source... Go to PubMed...
    14. Jönsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K, Abramo L, Fritzson I, Pekarski O, Runström A, Sandin H, Thuvesson I, Björk A. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3 - quinolinecarboxamides for treatment of autoimmune disorders: structure - activity relationship. J Med Chem 2004; 47: 2075-2088. Go to original source... Go to PubMed...
    15. Jordan CA, Friedrich Jr VL,Godfraind C, Cardellechio CB,Holmes KV. Dubois-Dalcq M. Expression of viral and myelin gene transcripts in a murine CNS demyelinating disease caused by a coronavirus.Glia 1989; 2: 318-329. Go to original source... Go to PubMed...
    16. Kuhlmann T, Lassmann H, Bruck W. Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol 2008; 115: 275-287. Go to original source... Go to PubMed...
    17. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656. Go to original source... Go to PubMed...
    18. Lessmann V, Gottmann K, Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003; 69: 341-374. Go to original source... Go to PubMed...
    19. Mishra M, Wang J, Silva C, Mack M, Yong V. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its pertubation by laquinimod. Am J Pathol 181; 645-651.
    20. Moore S, Khalaj AJ, Yoon JH, Patel R, Hannsun G, Yoo T, Sasidhar M, Martinez-Torres L, Hayardeny L, Tiwari-Woodruff SK. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination and improves motor deficit in a mouse model of multiple sclerosis. Brain and Behavior 2013; 3(6): 664-682. Go to original source... Go to PubMed...
    21. Riley CP, Cope TC, Buck CR. CNS neurotrophins are biologically active and expressed by multiple cell types. J Mol Histol 2004; 35: 771-783. Go to original source... Go to PubMed...
    22. Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010; 33: 202-210. Go to original source... Go to PubMed...
    23. Teitelbaum D, Arnon R, Sela M. Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 1997; 53: 24-28. Go to original source... Go to PubMed...
    24. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Ann Rev Neurosci 2008; 31: 247-269. Go to original source... Go to PubMed...
    25. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008; 131: 288-303. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.